Search the Site
Follow TheCancerLetter on Twitter
join our mailing list

Enter your name and email address to receive an update when we post new content.

IP Login


The Cancer Letter Inc.
PO Box 9905
DC 20016
Tel: 202-362-1809
Fax: 202-379-1787
publication date: Oct 1, 2015
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Cyramza Increases PFS In Phase II Study of Bladder Cancer Patients Who Failed Platinum Therapy


A phase II study of Cyramza (ramucirumab) in combination with docetaxel met its primary endpoint, demonstrating a statistically significant increase in progression-free survival for patients with locally advanced or metastatic urothelial carcinoma who failed prior platinum-based therapy.

Final results of the trial were presented at the European Cancer Congress in Vienna, Austria. Based on these findings, Eli Lilly & Co., the drug’s sponsor, recently initiated a phase III trial, called RANGE, which has begun to enroll patients.

To access this members-only content, please log in.

If you're not a subscriber why not join today?

If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.